Skip to main
GRI
GRI logo

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The financial analysis indicates that GRI Bio Inc's current valuation is considered attractive due to a significant upside potential as derived from a net present value (NPV) analysis. The company is poised to address unmet medical needs in areas such as inflammatory and autoimmune disorders, particularly through its promising product candidates, GRI-0621 and GRI-0803. Furthermore, the annual increase in cases of idiopathic pulmonary fibrosis (IPF), with over 40,000 new diagnoses, underscores the growing demand for innovative treatments, enhancing the company's market potential.

Bears say

GRI Bio Inc reported a significant net loss of $3.9 million, translating to an earnings per share (EPS) of $(7.72), which was worse than both the company's estimates and the consensus projections. The company's financial challenges are exacerbated by multiple risks, including liquidity concerns, potential failure of its product candidates to achieve safety and efficacy in clinical trials, and difficulties in gaining regulatory approvals. Additionally, external factors such as competition, shifting macroeconomic conditions, and varying investor sentiment in the biotech sector further contribute to the negative outlook for GRI Bio's stock.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.